Skip to main content
MD logo

MD · Pediatrix Medical Group, Inc.

Track MD — free
$29.94 -0.90 (-2.92%) At close · Nov 19
Market Cap
$2.34B
Shares
78.12M
Volume · Nov 19 597.16K Avg daily vol (3M) 714.52K

Price & Indicators

 

Key stats

Close
$29.94
Open
$30.41
Day range
$29.73–30.93
52-week closing range
$18.82–32.80
Average volume, 30 days
686K
Short interest
3.5M · 4.5% of shares · 5.0 days
Short volume, last session
68%
Last earnings
Oct 29, 2026
Latest filing
10-Q · Oct 29
Price history
Jan 2020 to Nov 2026

Up next

Feb 18, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Oct 29
Earnings call
Adjusted EBITDA hits $85 million; full-year outlook narrowed

Pediatrix Medical Group reported adjusted EBITDA of $85 million for the quarter and narrowed its full-year 2026 adjusted EBITDA outlook to $290 to $300 million. Same unit revenue was positive, with equal contributions from volume and pricing. The company repurchased just over 3 million shares in the quarter, bringing total buybacks since August of 2025 to 10 million shares.

4 source passages
We are pleased to report a strong quarter with adjusted EBITDA of $85 million. We are narrowing the range of our full-year 2026 outlook to $290 to $300 million in adjusted EBITDA. Same unit revenue was positive, with equal contributions from volume and pricing, even with pricing reflecting the lapping of the tailwinds we experienced from strong collection activity over the past several quarters. In the quarter, we repurchased just over 3 million shares of our stock, bringing our total buyback since August of 2025 to 10 million shares Open the document at this passage
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly net income falls to $47.0 million from $71.7 million

Pediatrix Medical Group's net income fell to $47.0 million for the three months ended September 30, 2026, from $71.7 million a year earlier, while Adjusted EBITDA was $85.5 million versus $87.3 million. Working capital dropped to $148.3 million as the Term A Loan, maturing in February 2027, was reclassified to current debt. Stock repurchases totaled $147.2 million in the nine months ended September 30, 2026.

Revenue $501.37M ▲ 1.7% Net income $46.99M ▼ 34.5% Diluted EPS $0.59 ▼ 29.8%
Read from the MD&A section
5 source passages
Net income was $47.0 million for the three months ended September 30, 2026, as compared to $71.7 million for the same period in 2025. Adjusted EBITDA was $85.5 million for the three months ended September 30, 2026, as compared to $87.3 million for the same period in 2025. Additionally, we had working capital of $148.3 million at September 30, 2026, a decrease of $156.3 million from working capital of $304.6 million at December 31, 2025. The net decrease in working capital is primarily due to an increase in the current portion of debt from the reclassification of the Term A Loan (as defined below), which matures in February 2027. Financing activities: During the nine months ended September 30, 2026, our net cash used in financing activities of $165.5 million consisted primarily of stock repurchases of $147.2 million and payments on our Term A Loan of $18.8 million. Open the document at this passage
Oct 29
Current report 8-K
Third-quarter EPS of $0.59 on $501.4 million net revenue

Pediatrix Medical Group reported third-quarter 2026 diluted earnings of $0.59 per share on net revenue of $501.4 million. Net income was $47.0 million, and Adjusted EPS was $0.72. The company expects full year 2026 Adjusted EBITDA of $290 million to $300 million.

Financial results
5 source passages
Pediatrix Medical Group reported earnings of $0.59 per share for the three months ended September 30, 2026. Pediatrix’s net revenue for the three months ended September 30, 2026 was $501.4 million Pediatrix generated net income of $47.0 million, or $0.59 per diluted share, for the 2026 third quarter For the third quarter of 2026, Pediatrix reported Adjusted EPS of $0.72 Pediatrix anticipates that its full year 2026 outlook for Adjusted EBITDA, as defined above, will be in a range of $290 million to $300 million. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.96B
Trailing 12 months
Net income (TTM)
$150.09M
Trailing 12 months
Revenue growth YoY
+1.7%
Year over year
Operating margin
10.9%
Trailing 12 months
P / E (TTM)
16.3
Trailing earnings · reciprocal yield 6.1%
FCF yield
—
TTM · current market cap
Return on invested capital
14.1%
Trailing 12 months
Net cash
−$265.80M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-6.9%
Year over year · fewer shares
Price change (1Y)
+30.6%
Trailing year
Short interest
4.5%
Latest settlement · 5.0 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26

TL;DR. Pediatrix reported Q2 2026 adjusted EBITDA of $76 million and reaffirmed its full-year 2026 adjusted EBITDA guidance of $280–$300 million, noting stable payor mix, strong RCM collections, and rising acuity, while same-unit patient volumes declined 2% and NICU days fell 3%.

Bullish
  • + Generated $76 million in Q2 adjusted EBITDA, in line with expectations
  • + Reaffirmed full-year 2026 adjusted EBITDA guidance of $280–$300 million
  • + Repurchased nearly 2 million shares in Q2, bringing total buybacks since August 2025 to 7 million shares and reducing share count to 81 million from 87 million
  • + Strong balance sheet with $289 million cash, ~1x leverage, and $126 million operating cash flow supports growth and capital returns
Bearish
  • − Same-unit patient service volumes declined 2%, with NICU days down 3%
  • − Management expects full-year 2026 volumes to be flat to slightly down
  • − RCM collections tailwind expected to dissipate in the second half of 2026
  • − Q2 operating cash flow of $126 million fell from $138 million in the prior-year quarter

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +22%
above
Price vs 50-day avg +6%
above
RSI (14) 49
neutral
MACD trend Negative
52-week position 80%
mid-range
Momentum
relative strength
Very Strong
1-month return +1%
trailing
6-month return +38%
trailing
YTD return +40%
this year
Relative strength +44%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $28 › 200d $25 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +37 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.54% of shares out · ▼ -18.9% MoM · 5.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
313 holders — near 3-yr high, broad support
Squeeze score 64
elevated · 0–100
Fundamentals
Strong
Revenue growth −5%
Y/Y
EPS growth +263%
Y/Y
Valuation P/E 16.3
below peers
Buyback $21.5M
remaining
Balance sheet $225.0M
net debt
Quant / Vol
risk profile
Moderate
Volatility 35%
annualized · 1-yr
Max drawdown −24%
past year
ATR 3.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Oct 29, 2026
Adjusted EBITDA · full year 2026 Non-GAAP Raised $290M – $300M
Aug 4, 2026 $280M – $300M changed to Oct 29, 2026 $290M – $300M
Previous outlook earlier release · from the Earnings Call filed Aug 4, 2026

Still-open targets the latest release did not restate under the same label.

G&A · 2026 $230M – $240M
Guided vs delivered · last 1 settled
Revenue 2022
guided $2B
$1.97B Miss −1.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+22% Bullish
Price vs 50-day avg
+6% Bullish
RSI (14)
49 Neutral
MACD trend
Negative Bearish
52-week position
80% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $28 › 200d $25 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +37 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.54% of shares out · ▼ -18.9% MoM · 5.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
313 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $19 Now $30 · 80% Range high $33
vs 200-day avg +22% vs 50-day avg +6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $134.6M the six months ended June 30, 2026 —
Adjusted EPS non-GAAP $1.07 the six months ended June 30, 2026 —
Adjusted income and diluted EPS non-GAAP $1.07 Six Months Ended June 30, 2026 —
Contracted managed care 72% the three months ended June 30, 2026 filing —
Government 23% the three months ended June 30, 2026 filing —
Growth in non-same unit activity 2.1% the three months ended June 30, 2026 —
Growth in same-unit revenue 1.9% the three months ended June 30, 2026 —
Hospital-based patient services volume change -2.8% the three months ended June 30, 2026 —
Neonatal intensive care unit (NICU) days change -3.2% the three months ended June 30, 2026 —
Office-based patient services volume change -1.2% the three months ended June 30, 2026 —
Other third-parties 4% the three months ended June 30, 2026 filing —
Percentage of services reimbursed by commercial and other non-government payors change 135 the 2026 second quarter —
Same-unit net revenue increase 1.9% the three months ended June 30, 2026 filing —
Same-unit revenue attributable to patient volume -2.1% the 2026 second quarter —
Same-unit revenue from net reimbursement-related factors 4% the 2026 second quarter —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MD
Pediatrix Medical Group, Inc.
this stock
$2.34B +40.0% -4.9% 16.3 4.5%
HCA
HCA Healthcare, Inc.
$96.16B -1.4% +7.1% 15.3 2.3%
FSNUY
Fresenius SE & Co. KGaA
$32.17B -0.3% — — 0.0%
THC
Tenet Healthcare Corp
$20.98B +32.6% +0.9% 7.6 2.2%
EHC
Encompass Health Corp
$12.98B +24.6% +10.5% 20.7 3.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
313
% held
105.8%
Net QoQ
-1.0M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
350
View
Short & Settlement
Short Interest Falling
Shares short
3.5M
Days to cover
5.0d
Change
-824.9K sh
View
Short Volume
Short vol %
68%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
2.2K
Value
$64.6K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
45.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$165.4M
EPS diluted
$1.94
View
Buybacks
Authorized
$250.0M
Remaining
$21.5M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 29, 2026
This year
15

Pediatrix Medical Group reported third-quarter 2026 diluted earnings of $0.59 per share on net revenue of $501.4 million. Net income was $47.0 million, and Adjusted EPS was $0.72. The company expects full year 2026 Adjusted EBITDA of $290 million to $300 million.

View
Proposed Sales
Value
$853.1K
Shares
36.0K
Filed
May 13, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 29, 2026
View
Investor Relations
Latest news
Pediatrix Medical Group Reports T…
Published
Oct 29, 2026
View

Performance

5D 20D 120D MTD YTD
MD -4.7% +1.3% +38.5% +0.4% +40.0%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +0.8% +7.6% +44.1% +5.7% +35.0%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$250.00M
Spent (derived)
$228.50M
Remaining
$21.50M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 893949 CUSIP 58502B106 13F (30d) 312 filings 284 filers Visit website Investor relations